Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | ME2 | P23368 | 6/20 | 0.51 |
| ▸ | ME1 | P48163 | 6/20 | 0.51 |
| ▸ | ME3 | Q16798 | 6/20 | 0.51 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12458573 | 0.81 | ME2 (0.59) | GPR119ME2ME1ME3SLC6A7 | |
| SCHEMBL23259338 | 0.81 | ME2 (0.59) | GPR119ME2ME1ME3SLC6A7 | |
| SCHEMBL5214510 | 0.81 | ME2 (0.57) | GPR119ME2ME1ME3SLC6A7 | |
| SCHEMBL30931813 | 0.81 | GPR119 (0.76) | GPR119ME2ME1ME3SLC6A7 | |
| SCHEMBL1103897 | 0.81 | GPR119 (0.76) | GPR119ME2ME1ME3SLC6A7 | |
| SCHEMBL6282474 | 0.80 | GPR119 (0.47) | GPR119ME2ME1ME3SLC6A7 | |
| SCHEMBL2312297 | 0.79 | GPR119 (0.58) | GPR119ME2ME1ME3SLC6A7 | |
| SCHEMBL3802326 | 0.79 | ME2 (0.56) | GPR119ME2ME1ME3SLC6A7 | |
| SCHEMBL23259131 | 0.79 | ME2 (0.59) | GPR119ME2ME1ME3SLC6A7 | |
| SCHEMBL2357897 | 0.78 | ME2 (0.55) | GPR119ME2ME1ME3SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| EP-2350000-A1 | PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | APP, APBA1, PSEN1 | GPR119 2464/4885ME2 4546/4885ME1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.